6-hydroxymethyl-2-naphthalenecarboxylic acid benzyl ester | 219316-42-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-hydroxymethyl-2-naphthalenecarboxylic acid benzyl ester
• 英文别名: benzyl 6-(hydroxymethyl)naphthalene-2-carboxylate
• CAS: 219316-42-4
• 化学式: C₁₉H₁₆O₃
• 分子量: 292.334
• InChiKey: ZYKIMGXJBSPRPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-hydroxymethyl-2-naphthalenecarboxylic acid benzyl ester 在 manganese(IV) oxide 、 aluminum oxide 、 lithium hydroxide 、 草酰氯 、 二甲基亚砜 、 三乙胺 、 4,4'-二氨基二苯乙烯-2,2'-二磺酸 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 6.08h， 生成 6-((bis-(tert-butyl))phosphono-difluoromethyl)-2-naphthoic acid
  参考文献：
  名称：

  Structure-based design and synthesis of small molecule protein–tyrosine phosphatase 1B inhibitors

  摘要：

  Protein-tyrosine phosphatase (PTP) inhibitors are attractive as potential signal transduction-directed therapeutics which may be useful in the treatment of a variety of diseases. We have previously reported the X-ray structure of 1,1-difluoro-1-(2-naphthalenyl)methyl] phosphonic acid (4) complexed with the human the protein-tyrosine phosphatase 1B (PTP1B) and its use in the design of an analogue which binds with higher affinity within the catalytic site (Burke, T. R., Jr. et al. Biochemistry 1996, 35, 15989). In the current study, new naphthyldifluoromethyl phosphonic acids were designed bearing acidic functionality intended to interact with the PTP1B Arg47, which is situated just outside the catalytic pocket. This residue has been shown previously to provide key interactions with acidic residues of phosphotyrosyl-containing peptide substrates. Consistent with trends predicted by molecular dynamics calculations, the new analogues bound with 7- to 14-fold higher affinity than the parent 4, in principal validating the design rationale. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00140-0
• 作为产物：
  描述：

  6-(benzyloxycarbonyl)-2-naphthoic acid 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 以84%的产率得到6-hydroxymethyl-2-naphthalenecarboxylic acid benzyl ester
  参考文献：
  名称：

  Structure-based design and synthesis of small molecule protein–tyrosine phosphatase 1B inhibitors

  摘要：

  Protein-tyrosine phosphatase (PTP) inhibitors are attractive as potential signal transduction-directed therapeutics which may be useful in the treatment of a variety of diseases. We have previously reported the X-ray structure of 1,1-difluoro-1-(2-naphthalenyl)methyl] phosphonic acid (4) complexed with the human the protein-tyrosine phosphatase 1B (PTP1B) and its use in the design of an analogue which binds with higher affinity within the catalytic site (Burke, T. R., Jr. et al. Biochemistry 1996, 35, 15989). In the current study, new naphthyldifluoromethyl phosphonic acids were designed bearing acidic functionality intended to interact with the PTP1B Arg47, which is situated just outside the catalytic pocket. This residue has been shown previously to provide key interactions with acidic residues of phosphotyrosyl-containing peptide substrates. Consistent with trends predicted by molecular dynamics calculations, the new analogues bound with 7- to 14-fold higher affinity than the parent 4, in principal validating the design rationale. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00140-0

文献信息

• Phosphate mimics and methods of treatment using phosphatease inhibitors
  申请人：Sugen, Inc.

  公开号：US20040138255A1

  公开（公告）日：2004-07-15

  The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase, and therefore are expected to be useful in the prevention and treatment of disorders associated with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurologic degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compounds containing fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell.

  本发明涉及三氟甲基磺酰和三氟甲基磺酰胺化合物及其生理上可接受的盐和前药。这些化合物预计能够调节与细胞信号转导相关的蛋白酪氨酸酶的活性，特别是蛋白酪氨酸磷酸酶，因此预计在预防和治疗与异常蛋白酪氨酸酶相关的细胞信号转导障碍，如癌症、糖尿病、免疫调节、神经退行性疾病、骨质疏松症和传染病方面有用。本发明还涉及含有氟甲基磺酰基团的化合物作为磷酸酯模拟物的用途。这些模拟物可用于抑制、调节或调节细胞中的磷酸结合蛋白的活性。
• Phosphate mimics and methods of treatment using phosphatase inhibitors
  申请人：Sugen, Inc.

  公开号：US06596772B1

  公开（公告）日：2003-07-22

  The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase, and therefore are expected to be useful in the prevention and treatment of disorders associated with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurologic degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compounds containing fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell.

  本发明涉及三氟甲基磺酰和三氟甲基磺酰胺化合物及其生理上可接受的盐和前药。这些化合物预计能够调节与细胞信号转导相关的蛋白酪氨酸酶的活性，尤其是蛋白酪氨酸磷酸酶，因此预计能够在预防和治疗与异常蛋白酪氨酸酶相关的细胞信号转导紊乱的疾病，如癌症、糖尿病、免疫调节、神经退行性疾病、骨质疏松症和传染病方面有用。本发明还涉及含有氟甲基磺酰基团的化合物作为磷酸盐类似物的用途。这些类似物可用于抑制、调节或调节细胞中的磷酸盐结合蛋白的活性。
• PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS
  申请人：Sugen, Inc.

  公开号：EP1212296A1

  公开（公告）日：2002-06-12
• US6596772B1
  申请人：——

  公开号：US6596772B1

  公开（公告）日：2003-07-22
• [EN] PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS<br/>[FR] MIMETIQUES PHOSPHATES ET PROCEDES DE TRAITEMENT UTILISANT DES INHIBITEURS DE PHOSPHATASE
  申请人：SUGEN INC

  公开号：WO2001016097A1

  公开（公告）日：2001-03-08

  The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase, and therefore are expected to be useful in the prevention and treatment of disorders associated with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurologic degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compounds containing fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell.